Clinical trial
Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
NCT06382168 is registered in ClinicalTrials.gov with Delta-Fly Pharma, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
- Lead sponsor
- Delta-Fly Pharma, Inc.
- Phase
- Phase 1/2
- Overall status
- Recruiting
- Start date
- June 12, 2024
- Completion date
- June 30, 2026
- Enrollment
- 39 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.